During the quarter, contribution from the export formulation business was lower; however, the company expects healthy ...

Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.

Stock analysts noted Natco Pharma’s missed consensus Q3 estimates on both revenue and Ebitda margin fronts due to lack of ...

Find all the latest Q3 results 2025 updates for TVS Srichakra, Rail Vikas Nigam, Shriram Properties, Ashok Leyland, Saint ...

The market turbulence also affected all sectoral indices, with Nifty Realty index losing 9.4%, Nifty Media falling 8%, and ...

Lupin and Natco receive US FDA approval for generic Tracleer tablets for oral suspension: Our Bureau, Mumbai Monday, February 10, 2025, 15:45 Hrs [IST] Global pharma major Lupin L ...

Hyderabad: NATCO Pharma Limited has announced final approval of its Abbreviated New Drug Application (ANDA) for Bosentan ...

The BSE Smallcap index fell 22 per cent from its peak as broader indices faced significant selling pressure this week due to ...

In the API segment, Natco has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides.Natco Pharma is also ...

All the sectoral indices ended in the red this week with Nifty Realty index shed 9.4 percent, Nifty Media fell 8 percent, ...

In the Indian stock market, FIIs are booking profits, domestic investors are treading carefully, and valuations are stretched ...